S -Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Despite the progressive increase in the number of antidepressants, many patients with major depressive disorder continue to be symptomatic. Clearly, there is an urgent need to develop better tolerated and more effective treatments for this disorder. The use of S-adenosyl methionine (SAMe), a naturally occurring molecule that serves as a methyl donor in human cellular metabolism, as adjunctive treatment for antidepressant nonresponders with major depressive disorder represents one such effort toward novel pharmacotherapy development. METHOD: Participants were 73 serotonin reuptake inhibitor (SRI) nonresponders with major depressive disorder enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe (target dose: 800 mg/twice daily). Patients continued to receive their SRI treatment at a stable dose throughout the 6-week trial. The primary outcome measure for the study was the response rates according to the 17-item Hamilton Depression Rating Scale (HAM-D). RESULTS: The HAM-D response and remission rates were higher for patients treated with adjunctive SAMe (36.1% and 25.8%, respectively) than adjunctive placebo (17.6% versus 11.7%, respectively). The number needed to treat for response and remission was approximately one in six and one in seven, respectively. There was no statistically significant difference in the proportion of SAMe- versus placebo-treated patients who discontinued the trial for any reason (20.6% versus 29.5%, respectively), due to adverse events (5.1% versus 8.8%, respectively), or due to inefficacy (5.1% versus 11.7%, respectively). CONCLUSIONS: These preliminary results suggest that SAMe can be an effective, well-tolerated, and safe adjunctive treatment strategy for SRI nonresponders with major depressive disorder and warrant replication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“administration of L-methylfolate and SAMe have demonstrated efficacy as adjuvant to antidepressant therapy”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Papakostas et al., 2010
In the citing paper
“Several placebo-controlled RCTs and two meta-analyses found SAMe, studied in doses of 200-1600mg per day, significantly more efficacious than placebo and equivalent to tricyclic antidepressants, in the treatment of depression, while a couple of studies report it equivalent to placebo [48-50].”
From Complementary and alternative medicine therapies for perinatal depression (2014) · cites this paper as [50]
In the citing paper
“In five trials of SAMe for cholestasis of pregnancy, there were an absence of adverse events or side effects for mothers or for their infants [50].”
From Complementary and alternative medicine therapies for perinatal depression (2014) · cites this paper as [50]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationStructured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 4,086
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationStructured Clinical Interview for DSM-III-R Personality Disorders
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2012) · PsycTESTS Dataset · doi:10.1037/t07827-000 · Cited by 1,403
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Self-citationBottiglieri, T. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.1151s · Cited by 286
S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies
Bressa, G. M. (1994) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb05403.x · Cited by 195
Evidence for S-Adenosyl-L-Methionine (SAM-e) for the Treatment of Major Depressive Disorder
Papakostas, G. I. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8157su1c.04 · Cited by 112
Self-citationEmpirical Testing of Two Models for Staging Antidepressant Treatment Resistance
Petersen, T., Papakostas, G. I., Posternak, M. A., Kant, A., Guyker, W. M., Iosifescu, D. V., Yeung, A. S., Nierenberg, A. A., & Fava, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169036.40755.16 · Cited by 110
Self-citation
Research works printed but not linked: 2
- 1994, American Psychiatric Publishing
- Alpert JE , Papakostas GI , Mischoulon D : One-carbon metabolism and the treatment of depression: roles of S-adenosyl-l-methionine and folate, in Natural Medications for Psychiatric Disorders: Considering the Alternatives, 2nd ed . Edited by , Mischoulon D , Rosenbaum J . Philadelphia, Lippincott Williams and Wilkins, 2008, pp 68–83
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Metadata
- Authors
- Papakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M.
- Affiliations
- Harvard University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2010-08-01
- Volume
- 167
- Issue
- 8
- Pages
- 942-948
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2164759779
- Cited by
- 297
- References
- 15
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 12 · 2023: 10 · 2022: 11 · 2021: 12 · 2020: 64 · 2019: 8 · 2018: 14 · 2017: 15 · 2016: 17 · 2015: 34 · 2014: 20 · 2013: 21 · 2012: 23
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (K23MH069629)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- S-adenosylmethionine, serotonin reuptake inhibitors, major depressive disorder, adjunctive therapy, treatment-resistant depression, adverse events
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Patient Dropouts, Placebos, Psychiatric Status Rating Scales, S-Adenosylmethionine, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: S -Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2009.09081198
- The paper
- Papakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M. (2010). S -Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2009.09081198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.